HCM News
Archived Headlines
- Week ahead: IPO calendar fills up 03/11/16
- Cancer drugs made in China: Hutchison China MediTech sets terms for $100 million US IPO 03/04/16
- Immunotherapy biotech Hutchison China MediTech files for a $100 million IPO 10/16/15
- Immunotherapy biotech Hutchison China MediTech files for a $100 million IPO 10/16/15
- Immunotherapy biotech Hutchison China MediTech files for a $100 million IPO 10/16/15
Bigger and better: 2016 IPOs that raised more than $100 million are up over 30%
The 21 IPOs this year that have raised raised over $100 million have delivered investors an average return of 32%, including a first-day pop of 14% and an additional 14% in the aftermarket. Most notably, only one IPO in this group currently trades below issue,...read more
Renaissance Capital's 1Q16 US IPO Market Review
The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing...read more
US IPO Weekly Recap: Two healthcare companies price amid an improving market backdrop
Of the three scheduled healthcare offerings this past week, only two priced. This marks a total of seven IPOs year to date, all from healthcare companies, which have been predominantly development stage biotechs supported by existing backers. While the broader...read more
Cancer therapies from China: Hutchison China MediTech prices $101 million US IPO at $13.50
Hutchison China MediTech, a CK Hutchison-backed pharmaceutical with a pipeline of oncology candidates, raised $101 million by offering 7.5 million ADSs at $13.50. In its most recent filing, the company expected to raise $100 million by offering 6.1 million ADSs...read more